Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203723 · ClinicalTrials.gov registry record · Phase 4
Use of Risperidone in ECT for Treatment Resistant Depression
A Phase 4 study, sponsored by University of California, Los Angeles.
- Terminated
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
NCT00203723 is a Phase 4 study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 45 participants.
The verdict
NCT00203723, a Phase 4 study, was terminated before completion, sponsored by University of California, Los Angeles.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination of risperidone and ECT improves a patient's response in depression compared to ECT alone.
Interventions
- DRUG Risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00203723
The ClinicalTrials.gov registry entry for NCT00203723 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Risperidone is the first listed.
NCT00203723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00203723 about?
NCT00203723 is a clinical study titled "Use of Risperidone in ECT for Treatment Resistant Depression". The purpose of this study is to determine if the combination of risperidone and ECT improves a patient's response in depression compared to ECT alone.
What is the current status of trial NCT00203723?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2005-03. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00203723?
The interventions under investigation include: Risperidone (DRUG).
Who is sponsoring clinical trial NCT00203723?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.